Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AbbVie has struck a second partnership with the neuroscience-focused gene-therapy firm Voyager Therapeutics. AbbVie is paying Voyager $65 million up front to develop gene therapies that contain instructions for making antibodies against the α-synuclein protein that accumulates in the brains of people with Parkinson’s disease. Voyager could earn up to $245 million in milestone payments after preclinical and Phase I clinical studies, and nearly $1.3 billion in added milestone payments. Last year, the two companies formed a similar pact to develop an Alzheimer’s gene therapy.
This article has been sent to the following recipient: